Deep Track Capital GERN Position
Active8-Fund ConvergenceDeep Track Capital trimmed their position in Geron Corporation (GERN) in Q4 2025, holding $42.9M worth of shares across 32,511,271 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
GERN is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Imetelstat in 806 days (Jun 30, 2028), making the timing of Deep Track's position particularly relevant.
Short interest stands at 10.3% of float with 3.2 days to cover, indicating significant bearish positioning against Deep Track's long thesis.
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Full company profile →Short Interest
10.3%
3.2 days to cover
Deep Track Capital GERN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 32,511,271 | -8,585,251 | $42.9M |
| Q3 2025 | Decreased | 41,096,522 | -1,903,478 | $56.3M |
| Q2 2025 | Increased | 43,000,000 | +4,823,749 | $60.6M |
| Q1 2025 | Increased | 38,176,251 | +34,164,964 | $60.7M |
| Q4 2024 | Decreased | 4,011,287 | -3,563,762 | $14.2M |
| Q3 2024 | Decreased | 7,575,049 | -5,424,951 | $34.4M |
| Q2 2024 | Decreased | 13,000,000 | -17,505,929 | $55.1M |
| Q1 2024 | Increased | 30,505,929 | +922,480 | $100.7M |
| Q4 2023 | Increased | 29,583,449 | +3,883,449 | $62.4M |
| Q3 2023 | Increased | 25,700,000 | +1,529,034 | $54.5M |
| Q2 2023 | Decreased | 24,170,966 | -2,696,513 | $77.6M |
| Q1 2023 | New | 26,867,479 | +26,867,479 | $58.3M |
Frequently Asked Questions
Does Deep Track Capital own GERN?
Yes. As of Q4 2025, Deep Track Capital holds 32,511,271 shares of Geron Corporation (GERN) valued at $42.9M. This data comes from their SEC 13F filing.
How many hedge funds own GERN?
8 specialist biotech hedge funds currently hold GERN, including RTW Investments, RA Capital Management, OrbiMed Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy GERN?
Deep Track Capital's position in GERN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's GERN position increasing or decreasing?
Deep Track Capital trimmed their GERN position in the most recent quarter, reducing by 8,585,251 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GERNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →